Gross Even-Zohar, N.; Pick, M.; Hofstetter, L.; Shaulov, A.; Nachmias, B.; Lebel, E.; Gatt, M.E.
CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival. J. Clin. Med. 2022, 11, 2913.
https://doi.org/10.3390/jcm11102913
AMA Style
Gross Even-Zohar N, Pick M, Hofstetter L, Shaulov A, Nachmias B, Lebel E, Gatt ME.
CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival. Journal of Clinical Medicine. 2022; 11(10):2913.
https://doi.org/10.3390/jcm11102913
Chicago/Turabian Style
Gross Even-Zohar, Noa, Marjorie Pick, Liron Hofstetter, Adir Shaulov, Boaz Nachmias, Eyal Lebel, and Moshe E. Gatt.
2022. "CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival" Journal of Clinical Medicine 11, no. 10: 2913.
https://doi.org/10.3390/jcm11102913
APA Style
Gross Even-Zohar, N., Pick, M., Hofstetter, L., Shaulov, A., Nachmias, B., Lebel, E., & Gatt, M. E.
(2022). CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival. Journal of Clinical Medicine, 11(10), 2913.
https://doi.org/10.3390/jcm11102913